Amneal Pharmaceuticals, Inc. (AMRX)

Every figure this model derived for AMRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 72,943,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 127,637,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,947,029,000 AssetsCurrent 2026-06-30
current liabilities 883,187,000 LiabilitiesCurrent 2026-06-30
equity 33,024,000 StockholdersEquity 2026-06-30
interest expense 176,950,000 InterestPaidNet 2026-06-30
ocf 200,778,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,117,548,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 35,629,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AMRX on one particular measure came for.

RatioValue
cash operating margin17.54
current ratio2.2
current ratio reported2.2
dilution pct5.13
ebit yoy20.62
fcf margin4.1
growth cv0.48
interest cover2.57
net debt ebitda4.79
operating margin14.56
owner earnings margin2.96
revenue growth9.28
revenue growth per share3.95
roic14.45
rule of 4023.84
sbc pct revenue1.14

What to be careful about

What this model itself distrusts about AMRX's figures. Written by the derivation as it ran, not added afterwards.